VEGFA and glioblastoma: As GBM is one of the most vascularized tumors, antiangiogenic therapies have been developed, such us, among others, gene therapy blocking the vascular endothelial growth factor (VEGF)-dependent pathway,[8] or bevacizumab, a humanized IgG1 monoclonal antibody that selectively binds and blocks VEGF.[9] Besides the aforementioned therapies, gene therapy, immunotherapy,[10] vaccine therapy,[11] or stem cell therapy[12] are also being studied.